TLR4 and melanoma: TriMixDC-MEL [12], a cellular vaccine based on autologous monocyte-derived dendritic cells (DC) electroporated with synthetic messenger RNA (mRNA) encoding CD40 ligand, a constitutively active Toll-like receptor 4 and CD70, together with mRNA encoding fusion proteins of a human leukocyte antigen (HLA)-class II targeting signal (DC-LAMP) coupled to a melanoma-associated antigen (either MAGE-A3, MAGE-C2, tyrosinase or gp100) has anti-tumoral activity in patients with advanced melanoma [13].